Abstract
How can small to medium-sized pharma and biotech companies enhance the chances of running a successful drug project and maximise the return on a limited number of assets?
Having a full appreciation of the safety risks associated with proposed drug targets is a critical element in understanding the unwanted side-effects that might stop a project in its tracks. Having this information is necessary to complement knowledge about the likely efficacy of a future drug. However, the lack of data-rich insight into drug target safety is one of the major causes of drug project failure today.
Conducting comprehensive target safety reviews early in the drug discovery process enables drug project teams to make the right decisions about which drug targets to take forward.
Having a full appreciation of the safety risks associated with proposed drug targets is a critical element in understanding the unwanted side-effects that might stop a project in its tracks. Having this information is necessary to complement knowledge about the likely efficacy of a future drug. However, the lack of data-rich insight into drug target safety is one of the major causes of drug project failure today.
Conducting comprehensive target safety reviews early in the drug discovery process enables drug project teams to make the right decisions about which drug targets to take forward.
| Original language | English |
|---|---|
| Pages (from-to) | 1925-1928 |
| Number of pages | 3 |
| Journal | Drug Discovery Today |
| Volume | 23 |
| Issue number | 12 |
| Early online date | 24 May 2018 |
| DOIs | |
| Publication status | Published - 1 Dec 2018 |
Keywords
- Drug Discovery
- target safety assessment
- attrition
- risk mitigation